Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | Cytarabine + Olutasidenib |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Cytarabine | Cytosar-U | Ara-C | Cytosar-U (cytarabine) is a cytidine analog that, when incorporated into DNA, inhibits DNA synthesis and repair (PMID: 32524309). | |
Olutasidenib | FT-2102 | IDH1 Inhibitor 8 | Olutasidenib (FT-2102) specifically targets IDH1 with mutations at amino acid R132, which results in decreased 2HG production and potentially leads to increased differentiation and decreased proliferation of IDH R132-mutant cancer cells (PMID: 31971798). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02719574 | Phase I | Cytarabine + Olutasidenib Olutasidenib Azacitidine + Olutasidenib | Open-label Study of FT-2102 With or Without Azacitidine or Cytarabine in Patients With AML or MDS With an IDH1 Mutation | Active, not recruiting | USA | ITA | FRA | ESP | DEU | CAN | 3 |